South Korean pharmaceutical company Boryung (KRX:003850) secured a supply agreement for taxotere exports from China's Yifan Pharmaceutical (SHE:002019), according to a Tuesday filing with the Korea Exchange.
The contract is valued at 383.65 billion won and is valid till Sept. 20, 2033.
Shares of Boryung rose nearly 2% in recent trade.